The mainstay of therapy for peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome is the class of medications known as the proton pump inhibitors (PPIs). Omeprazole, the prototype of this group belongs to the chemical class of benzimidazoles; substitution of R groups account for the variation in properties and side-effect profile of the different members of this drug class. The highly potent blocker of gastric acid secretion, this class of medications exerts their effects via a dose-dependent inhibitory action on hydrogen-potassium ATPase proton pump located on the luminal side of the gastric parietal cell. Proton pump inhibitors are mostly indicated in the treatment of chemotherapy induced GERD, in addition, they are first line agents for the treatment of dyspepsia, Helicobacter Pylori eradication, and the prevention and treatment of non-steroidal anti-inflammatory drugs (NSAIDs) and glucocorticosteroid-induced ulcers. There is evidence to support the use of PPIs for treatment of hemoptysis and to limit the incidence of rebleeding palliative patients with peptic ulceration, for metastatic oesophagal and gastric carcinoma. The side effect profiles vary with each drug and there is potential for drug interactions especially in the setting of polypharmacy among palliative care patients. Med Pract 2019; 13, 2: 95-100 
Introduction
The mainstay of therapy for peptic ulcer disease, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome is the class of medications known as the proton pump inhibitors (PPIs) [1] . Omeprazole, the prototype of this group belongs to the chemical class of benzimidazoles; substitution of R groups account for the variation in properties and side-effect profile of the different members of this drug class. Highly potent blockers of gastric acid secretion, this class of medications exert their effects via a dose-dependent inhibitory action [2] on the proton pump, also known as, hydrogen-potassium ATPase located on the luminal side of the gastric parietal cell.
PPIs have very specific uses in Barrett's esophagus; esophagitis; GERD [4] ; peptic ulcer disease;
Helicobacter pylori eradication; upper gastrointestinal bleeding; prevention and treatment of non-steroidal anti-inflammatory drugs (NSAIDs) -induced ulcers and the prevention and treatment of ulcers induced by NSAIDs and glucocorticosteroids (GCs) co-administration [5] , for gastroprotective effect, whereas sole administration of GCs does not always warrant the use of PPIs. In addition, they are first-line agents for the treatment of dyspepsia (epigastric pain, heart burn and regurgitation) (Table 1) [6] .
Indications for proton pump inhibitors use in palliative care
In addition to the above-mentioned indications, PPIs are very specific uses in palliative care settings: they are especially important for chemotherapy-in-duced GERD, in order to decrease the volume of secretions in case of vomiting secondary to gastrointestinal obstruction [7, 8] . There is evidence to support the use of PPIs for the treatment of hemoptysis and to limit the incidence of rebleeding palliative patients with peptic ulceration [9] .
PPIs have been used for metastatic esophageal and gastric carcinoma [10, 11] . In one study, sodium rabeprazole significantly improved GERD symptoms in patients treated with gemcytabine and S-1 for pancreatic cancer [12] . PPIs are also useful for dyspepsia, albeit with unsatisfactory results in some palliative care patients.
Adverse effects of proton pump inhibitors
Despite their notable safety profile, PPIs have notable adverse effects which are well-documented in the literature [13] . These adverse effects may be systemic including acute inflammatory renal impairment via an immunological mechanism [14] ; increased incidence of Clostridium difficile infections; hip fractures, intestinal polyps, respiratory tract infections and pneumonia, megaloblastic anemia, Fe-deficiency (microcytic) anemia, hypomagnesemia, increased risk of helicobacter pylori infections, increased risk of disturbances in gut microbiota followed by colonization of intestine, diarrhea, short bowel obstruction (SBO), and spontaneous bacterial peritonitis (SBP), higher prevalence of dementia as well as higher risk of hip fractures ( Table 2 ). Through a similar mechanism of gut microbiota alteration, the use of PPIs has been associated with a higher risk of encephalopathy in patients with liver insufficiency [15, 16] . PPIs are also known to increase the incidence of heart failure exacerbations even among patients in palliative care [17, 18] . Finally, studies have shown an increased risk of death in patients in patients older than 65 years of age [19] .
Drug-drug interactions
PPIs are a well-tolerated class of drugs, with only a few side effects noted clinically. However, this class of drugs interact with other drugs through a wide variety of mechanisms (Table 3 ). Therefore, the use of PPIs concurrently with other medications may precipitate the failure of treatment or drug toxicity due to malabsorption, or excessive levels. Among the class of PPIs, interactions are most studied with omeprazole and esomeprazole [20] .
PPIs, especially Na-pantoprazole may interact with other medications by altering gastric acidity which may affect solubility and absorption of these medications. Raising gastric pH greatly limits the absorption of certain drugs including mycophenolate mofetil, itraconazole, ketoconazole [20] , atazanavir, digoxin, erlotinib, FeSO4, metronidazole suspension [10] .
PPIs are metabolized by the cytochrome P450 (CYP) family of enzymes, thus may modify the metabolism of other drugs through the CYP enzyme system. Omeprazole is the most widely studied for its interaction via this mechanism. Its strong affinity for CYP2C19 and moderate affinity for CYP3A4 makes it very likely to alter the pharmacokinetics of other drugs. Protease inhibitors are notable for this interaction: ritonavir, atazanavir, nelfinavir, saquinavir, indinavir. Raltegravir, an integrase inhibitor is also known for this. Moclobemide, diazepam, proguanil, phenytoin, warfarin which are largely metabolized by CYP2C19 are altered via competitive inhibition with omeprazole [20, 21] . Despite its significant pharmacokinetic interaction, several medications including antacids, bortezomib, ciprofloxacin extended release, gemifloxacin, nifedipine, metoprolol, NSAIDs, iron and theophylline, have not been found to interact with omeprazole [20] .
The S-enantiomer of omeprazole is esomeprazole. It is metabolized by a major pathway, CYP2C19 and to a lesser extent by CYP3A4 [10] . The metabolites of esomeprazole include the hydroxy-and 5-O-desmethyl [22] . Lansoprazole is metabolized by a major pathway, CYP2C19 and a minor pathway, CYP3A4. It is a moderate inhibitor of CY-P2C19 and glycoprotein P [20] as well as an inducer of CYP1A2. Its metabolites are inactive and eliminated in bile and urine [10] . Dexlansoprazole, the R-enantiomer of lansoprazole, is comparatively more efficacious [23] . In addition, investigations have shown that it may be taken regardless of meal time schedule [24] . It is metabolized by CYP2C19 and CYP3A4 and is known to interact with atazanavir, nelfinavir, rifampicin, St. John's wort, and fluvoxamine [23, 25] . Pantoprazole demonstrates a strong affinity for CYP2C19, CYP3A4, CYP2C8 and CYP2C9 [4, 10] . Rabeprazole is metabolized through both CYP2C19 and CYP3A4 pathway. It is a moderate inhibitor of CYP2C19 as well as an inducer 
Routes of administration and dosing
PPIs are administered mostly via an oral route with different bioavailability rates (Table 4 ). PPIs are available in different formulations ranging from capsules, tablets, immediate release, prolonged release, to subcutaneous and intravenous (omeprazole, pantoprazole) formulations. They include esomeprazole, dexlansoprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole. They are dosed from 10 mg to 40 mg, once or twice daily or 80 mg daily parenterally. All drugs in this class have similar efficacy [3] . Dose adjustments for PPIs are necessary in cases of liver impairment and sometimes, in the elderly, renal failure does not affect the metabolism of the drugs (Table 5 ).
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Conclusions and therapeutic implications
PPIs administration in the presence of suspicion of neoplastic disease must be withheld until the diagnosis of cancer has been established. PPIs may mask the symptoms of cancer thus diagnosis may be delayed.
Non-characteristic symptoms like fatigue, dizziness, drowsiness, as well as arrhythmias (are due to dyselectrolytemia e.g. hypomagnesemia) which develop insidiously in the setting of PPI use, should raise suspicion of the unwanted effect of the drug. Withdrawal of the drug is followed by normalization of electrolytes.
There is potential for drug interactions especially in the setting of polypharmacy among palliative care patients.
PPIs increase the risk of colonic polyps which may progress to cancer, therefore the use of PPIs must be limited to cases where absolutely necessary.
PPIs increase the risk of respiratory tract infections with resultant need for antibiotics. Since many physicians prescribe PPIs as a gastroprotective drug during antibiotic therapy, this creates a vicious cycle.
Streszczenie
Podstawą leczenia choroby wrzodowej, choroby refluksowej przełyku (GERD, gastroesophageal reflux disease) oraz zespołu Zollingera-Ellisona jest grupa leków znana jako inhibitory pompy protonowej (PPI, proton pump inhibitors). Omeprazol, prototyp tej grupy, należy do grupy chemicznej benzinidazoli; wymiana grupy R odpowiada za zróżnicowanie profilu działań niepożądanych oraz właściwości różnych leków z tej grupy. Będąc wysoko skutecznym blokerem wydzielania kwasu żołądkowego, ta grupa leków działa poprzez zależne od dawki działanie hamujące na pompę protonową APTazy wodorowo-potasowej zlokalizowaną po luminalnej stronie komórek okładzinowych. Stosowanie PPI wskazane jest najczęściej w leczeniu choroby refluksowej przełyku wywołanej przez chemioterapię; są one ponadto lekami pierwszego wyboru w leczeniu niestrawności, zwalczaniu bakterii Helicobacter pylori oraz w zapobieganiu i leczeniu wrzodów wywołanych lekami z grupy NLPZ oraz glukokortykosteroidami. Istnieją dowody na fakt, że PPI mają zastosowanie w leczeniu krwioplucia oraz ograniczaniu występowania nawrotów krwawienia u pacjentów paliatywnych z chorobą wrzodową, a także w przypadkach rozsianego raka przełyku oraz żołądka. Profil działań niepożądanych jest inny dla każdego leku; mogą one potencjalnie wchodzić w interakcje, w szczególności w warunkach polipragmazji wśród chorych poddawanych opiece paliatywnej.
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Wprowadzenie
Podstawą leczenie choroby wrzodowej, choroby refluksowej przełyku (GERD, gastroesophageal reflux disease) oraz zespołu Zollingera-Ellisona jest grupa leków znana jako inhibitory pompy protonowej (PPI, proton pump inhibitors) [1] . Omeprazol, prototyp tej grupy, należy do grupy chemicznej benzinidazoli; wymiana grupy R odpowiada za zróżnicowanie profilu działań niepożadanych oraz właściwości różnych leków z tej grupy. Będąc wysoko skutecznym blokerem wydzielania kwasu żołądkowego, ta grupa leków działa poprzez zależne od dawki działanie hamujące [2] na pompę protonową, znaną też jako APTaza wodorowo-potasowa zlokalizowana po luminalnej stronie komórki okładzinowej.
